Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 22 of 198 for:    Oral Cancer | ( Map: Mexico )

Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01095003
Recruitment Status : Completed
First Posted : March 29, 2010
Results First Posted : September 13, 2019
Last Update Posted : September 13, 2019
Information provided by (Responsible Party):
Pierre Fabre Medicament

Brief Summary:
The increasing use of anthracyclines and taxanes in the adjuvant, neoadjuvant and first-line metastatic settings, led to a raise of patients presenting with metastatic breast cancer after treatment with these agents. Options for the treatment of patients who have progressed after an anthracycline and a taxane are limited. The high level of in-vitro synergy of vinflunine combined with 5-fluorouracil (5-FU) together with the good tolerance and the encouraging response rate observed while combining IV vinflunine to oral capecitabine make it a promising combination to investigate further in a phase III trial. This phase III trial will evaluate the effectiveness and the safety profile of such combination for the treatment of patient with advanced breast cancer previously treated with or resistant to anthracycline and taxane resistant.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Vinflunine plus Capecitabine Drug: Capecitabine Phase 3

Detailed Description:

This multicentre, open-label, randomised, Phase III study will enrol 764 patients with advanced breast cancer who have previously been treated with or are resistant to an anthracycline and who are taxane resistant. Patients will be randomised in a 1:1 ratio to receive vinflunine plus capecitabine (Arm A) or capecitabine alone (Arm B).

Randomisation will be stratified according to a minimization procedure:

  1. Resistance to anthracyclines ("yes" versus "no"), Relapse ≤ 12 months in the adjuvant or neoadjuvant setting or progression ≤ 4 months in the metastatic setting,
  2. Karnofsky performance status ("90-100" versus "70-80"),
  3. Measurable disease ("yes" versus "no"),
  4. The number of prior lines of chemotherapy in the metastatic setting ("0" versus "1" versus "> 1") and,
  5. Study site.

Patients randomised in Arm A will receive:

  • Vinflunine at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a 20-minute i.v. infusion and,
  • Capecitabine which will be self-administered by the patient in an outpatient setting. Patients will take 825 mg/m² twice daily per os for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest. A cycle of therapy is defined as 3 weeks.

For patients randomised in Arm B, capecitabine will be self administered by the patient in an outpatient setting. Patients will take 1250 mg/m² twice daily per os for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest. A cycle of therapy is defined as 3 weeks.

The doses and timing of treatment will be modified based on toxicities experienced by the patient.

Patients will be assessed for toxicity, tumour response and progression at regular intervals during treatment. Patients will be evaluated for safety if they received any study drug. Laboratory values, adverse events and other symptoms will be graded.

Tumour response, progression-free survival and duration of response will be evaluated for all randomised patients. Tumour assessment is to be performed every 6 weeks (+/- 3 working days) from randomisation (regardless of the timing of treatment cycles) until disease progression is documented. Patients who discontinue protocol treatment for reasons other than disease progression will have tumour assessments every 6 weeks until documented disease progression. Patients may continue to receive additional cycles of therapy until progressive disease or intolerable toxicity.

Quality of Life assessment, will be measured by EORTC QLQ-C30 and QLQ-BR23 questionnaires, which will be completed by patients.

The primary endpoint for the trial is progression free survival calculated from the date of randomization until the date of progression or the date of death whatever the reason of death. The analysis of Progression-Free Survival is planned to take place when 615 progressions or deaths have been observed. One interim safety analysis is planned and will take place when 50 patients of each arm have completed at least one cycle of study treatment. It is anticipated that up to 170 active study centres will participate, and that accrual will be completed in approximately 30 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 770 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.
Study Start Date : May 2009
Actual Primary Completion Date : December 2011
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Vinflunine plus Capecitabine

Patients received (in combination with capecitabine)

• Vinflunine at the dose of 280 mg/m² and as a 20-minute IV. infusion on day 1 of each cycle repeated every 3 weeks.

Drug: Vinflunine plus Capecitabine

Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks

Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks

Other Names:
  • L00070 IN

Active Comparator: Capecitabine single-agent
Capecitabine at the dose of 825mg/m² per os twice per day each morning and each evening for 14 consecutive days beginning on day 1 of each cycle repeated every 3 weeks (self-administered).
Drug: Capecitabine
Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
Other Name: XELODA

Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: Baseline up to 2 years 7 months ]

    PFS is defined as time from date of randomization to date of the first documentation of objective tumor progression (according to the Independent Response Review Committee (IRC) and based on RECIST version 1.1) or death due to any cause.

    The PFS was primarily analysed in the Intent-to-treat (ITT) population. Patients lost to follow-up, or without a known record of progression or death at time of analysis had the progression-free survival censored at the date of last tumour assessment or the date of last contact of a follow-up showing no progression, whichever occurs last.

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: Baseline upto 3 years 10 months ]
    The overall survival (OS) was defined as the duration between the date of randomisation and the date of death from any cause. The OS analysis was performed in the ITT population and the eligible and per protocol populations once the required number of events (631 deaths) was observed Patients lost to follow-up, or without a known record of death at time of analysis had the OS censored at the date of last contact.

  2. Overall Response Rate (ORR) [ Time Frame: Baseline upto 2 years 7 months ]
    ORR defined as documentation of complete or partial response that was subsequently confirmed to first documentation of disease progression or to death due to any cause, whichever occurred first.

  3. Disease Control Rate [ Time Frame: Baseline up to 2 years 7 months ]
    Disease control rate defined (DCR) as the sum of confirmed complete response, confirmed partial response and stabilisation rate.

  4. Duration of Response [ Time Frame: Baseline up to 2 years 7 months ]
    Measured from the first time that measurement criteria were first met for objective response (documented CR or PR) until recurrence/progression or death whatever the cause.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • female patients
  • 21 years of age or older
  • histologically/cytologically confirmed carcinoma of the breast
  • documented locally recurrent or metastatic disease not amenable to curative surgery or radiotherapy
  • either one, two or three prior chemotherapy regimens
  • prior treatments including both an anthracycline and a taxane and patient no longer candidate for these drugs
  • measurable or non-measurable disease according to RECIST 1.1
  • Karnofsky performance score of at least 70 %
  • adequate haematological, hepatic and renal functions
  • ECG without clinically relevant abnormality

Exclusion Criteria:

  • known or clinical evidence of brain metastasis or leptomeningeal involvement
  • pulmonary lymphangitis or symptomatic pleural effusion
  • any serious, concurrent uncontrolled medical disorder
  • history of second primary malignancy
  • preexisting motor/sensory peripheral neuropathy
  • known history of HIV infection
  • prior therapy with capecitabine and/or vinca-alkaloids
  • history of severe hypersensitivity to vinca alkaloids and/or to fluoropyrimidine or contra indication to any of these drugs
  • known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency
  • pregnancy or breast feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01095003

Hide Hide 110 study locations
Layout table for location information
Buenos Aires, Argentina
Quilmes, Argentina
Rosario, Argentina
San Martin, Argentina
Tucuman, Argentina
Gomel, Belarus
Grodno, Belarus
Minsk, Belarus
Vitebsk, Belarus
Bruxelles, Belgium
Liège, Belgium
Curitiba, Brazil
Porto Alegre, Brazil
Santo Andre, Brazil
Sao Paulo, Brazil
Plovdiv, Bulgaria
Sofia, Bulgaria
Stara Zagora, Bulgaria
Brno, Czechia
Jihlava, Czechia
Tallinn, Estonia
Angers, France
Caen, France
Dijon, France
Le Mans, France
Lorient, France
Lyon, France
Montpellier, France
Nantes, France
Saint-Brieuc, France
Saint-Cloud, France
Saint-Herblain, France
Tours, France
Villejuif, France
Budapest, Hungary
Szekesfehervar, Hungary
Szolnok, Hungary
Aurangabad, India
Bangalore, India
Bhopal, India
Calcutta, India
Calicut, India
Jaipur, India
Mumbai, India
Patna, India
Pune, India
Trivandrum, India
Avellino, Italy
Cagliari, Italy
Cremona, Italy
Fabriano, Italy
Milano, Italy
Monza, Italy
Padova, Italy
Pisa, Italy
Rozzano, Italy
Verona, Italy
Chihuahua, Mexico
Leon, Mexico
Mexico City, Mexico
Saltillo, Mexico
Bialystok, Poland
Gdansk, Poland
Krakow, Poland
Lodz, Poland
Lubin, Poland
Warsawa, Poland
Russian Federation
Arkhangelsk, Russian Federation
Chelyabinsk, Russian Federation
Moscow, Russian Federation
Ryazan, Russian Federation
Saratov, Russian Federation
St-Petersburg, Russian Federation
Stavropol, Russian Federation
Tambov, Russian Federation
Ufa, Russian Federation
Vladimir, Russian Federation
Volgograd, Russian Federation
Nis, Serbia
Sremska Kamenica, Serbia
South Africa
Durban, South Africa
Kimberley, South Africa
Pretoria, South Africa
Sandton, South Africa
Barcelona, Spain
Lleida, Spain
Madrid, Spain
Oviedo, Spain
Valencia, Spain
Genolier, Switzerland
Lausanne, Switzerland
Winterthur, Switzerland
Taipei, Taiwan
Taoyuan, Taiwan
Cherkasy, Ukraine
Dnipropetrovsk, Ukraine
Donetsk, Ukraine
Khmelnytskyï, Ukraine
Kyiv, Ukraine
Simferopol, Ukraine
United Kingdom
Belfast, United Kingdom
Chelmsford, United Kingdom
Keighley, United Kingdom
London, United Kingdom
Nottingham, United Kingdom
Peterborough, United Kingdom
Portsmouth, United Kingdom
Sheffield, United Kingdom
Southend-on-Sea, United Kingdom
Sutton, United Kingdom
Sponsors and Collaborators
Pierre Fabre Medicament
Layout table for investigator information
Study Director: Jean-Claude VEDOVATO Pierre Fabre Medicament

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Pierre Fabre Medicament Identifier: NCT01095003    
Other Study ID Numbers: L00070 IN 305 B0
2008-004171-21 ( EudraCT Number )
First Posted: March 29, 2010    Key Record Dates
Results First Posted: September 13, 2019
Last Update Posted: September 13, 2019
Last Verified: August 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators